Ocean Biomedical, Inc. is a Providence, Rhode Island-based biopharma company with an innovative business model that ...

The final patient completing our pivotal F351 Phase 3 trial marks an important milestone for Gyre and our development pipeline. We are grateful to the patients, researchers, trial investigators, and ...

GSK is pumping £50 million (about $65 million) into a five-year collaboration with the University of Cambridge and Cambridge ...

The National Institutes of Health has awarded $2.9 million to Arkansas Children's Research Institute to examine how a critical therapy for patients with cystic fibrosis might become even more ...

Structure Therapeutics has the potential to have a best-in-class GLP-1 agonist drug for treatment of patients with obesity. Learn more on GPCR stock here.

Contineum Therapeutics (CTNM) stock gains as Baird launches coverage with an Outperform rating, highlighting the potential of ...

The Pulmonary Fibrosis Foundation (PFF), the nation's leading pulmonary fibrosis (PF) research, education and advocacy ...

The global Progressive Pulmonary Fibrosis (PPF) Treatment Market is set to achieve a valuation of USD 3.72 million in 2023, ...

The RespiriNTM project has received funding from the Innovative Health Initiative 2 Joint Undertaking (JU) under grant agreement No 853932. This Joined Undertaking receives support from the European ...

HEARTBREAKING tributes have flooded in for a mum-of-two who died 27 years after receiving a triple transplant. Deirdre Roche ...

In cases of pulmonary fibrosis attributable to interstitial lung disease, whether the aetiology is known or unknown, the ...

AN INSIGHTFUL session on the future of lung transplantation presented at this year’s European Respiratory Society (ERS) ...